Published: September 2014, Bio Medical Research International https://celltheranostics.com/wp-content/uploads/2019/11/Patched-Targeting-Peptides-for-Imaging-and-Treatment-of-Hedgehog-Postive-Breast-Tumors.pdf
ReadCENTENNIAL, Colo., April 9, 2013—Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study…
ReadThird License Completes the Company’s Initiative to Secure a Strong Pharmaceutical Partner for the South Korean Market CENTENNIAL, Colo.,…
ReadPublished: January 2013, Vol. 20, No. 1, Academic Radiology https://celltheranostics.com/wp-content/uploads/2019/11/Deveopment-of-99mTc-EC-tyrosine-for-Early-Detection-of-Breast-Cancer-Tumror-Response-to-the-Anticancer-Drug-Melphalan.pdf
ReadCENTENNIAL, Colo., September 11, 2012 – Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical…
ReadCENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the…
ReadCENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the…
ReadCENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for…
ReadCell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with…
ReadCell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s…
Read